Previous 10 | Next 10 |
Recent recommendations or guidances, from Canada and Egypt, expand the global recognition of this important therapy and its demonstrated favorable outcomes study results DUBLIN, Ireland and BRIDGEWATER, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) t...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buying stocks that are inexpensive is not the same thing as buying cheap stocks, though individual investors often conflate the two. Cheap means a stock is selling at a price that’s lower than its actual value. It&...
A new analysis supported by Amarin Corporation ([[AMRN]] +1.1%) and presented at the ongoing International Stroke Conference 2021 highlights the clinical impact of VASCEPA® (icosapent ethyl), the company announced.The presentation of REDUCE-IT® STROKE as announced by HLS Therapeutic...
HLS Therapeutics ([[HLTRF]]) announces that Amarin's ([[AMRN]] +3.0%) VASCEPA showed a 28% and 32% significant reductions in first and total strokes compared to placebo, and resulted in reductions in first and total ischemic strokes by 36%, without increasing hemorrhagic stroke, in ...
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2020 Q4 earnings call. For further details see: Amarin Corporation plc 2020 Q4 - Results - Earnings Call Presentation
Amarin Corporation plc (AMRN) Cowen 41st Annual Health Care Conference March 01, 2021 10:20 AM ET Company Participants Ken Cacciatore - Amarin John Thero - President and CEO Conference Call Participants Presentation Ken Cacciatore Great. I wanted to thank John for joining us on our Fireside C...
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q4 2020 Earnings Call Feb 25, 2021 , 7:30 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q4 2020 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q4 2020 Earnings Conference Call February 25, 2021 7:30 AM ET Company Participants Alina Doubrovna - Associate Manager of Investor Relations John Thero - President and Chief Executive Officer Michael Kalb - Chief Financial Officer Aaron Berg - Chief Commercial Of...
2020 was an outright disaster for Amarin (NASDAQ: AMRN) . Its stock plunged 77% because the drugmaker lost a key patent lawsuit over its flagship product Vascepa. But 2021 has been much better for Amarin so far. Good news related to the initiation of the regulatory review process ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...